4547:TYO
Kissei Pharmaceutical Co Ltd
3 705,00 JP¥
arrow_upward
+0,27%(+10,00) 1D
9 հոկ, 14:30:35 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
3 725 JP¥
High
3 745 JP¥
Low
3 705 JP¥
Mkt. cap
172,44 մլրդ
Avg. vol.
69,32 հզր
Volume
39,60 հզր
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
10,98
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 մլն
No. of employees
2 հզր
Open
3 725 JP¥
High
3 745 JP¥
Low
3 705 JP¥
Mkt. cap
172,44 մլրդ
Avg. vol.
69,32 հզր
Volume
39,60 հզր
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
10,98
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Yahoo Finance UK
·
51 րոպե առաջ
Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company
The Lufkin Daily News
·
1 ժամ առաջ
FILE PHOTO: Traders react to the Fed rate announcement on the floor of the NYSE in New York
dailyrecordnews.com
·
58 րոպե առաջ
Asian shares are mixed and crude prices fall after an unsettled day on Wall St
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 հզր
Founded09 օգս, 1946 թ.
HeadquartersՄացումոտո, Nagano, Ճապոնիա
Sector-
Websitekissei.co.jp